Crispr Therapeutics AG (CRSP) Stock Forecast (2026)
📈 CRISPR Therapeutics AG (CRSP) trades at $56.56 with a Wall Street consensus target of $80.00, suggesting 41.4% upside potential.
💼 Insiders have executed a net buying position, purchasing $52.7 million in shares against only $18.5 million in sales.
📊 Analysts forecast next year's revenue to surge by 283% to $61.2 million driven by the company's pipeline.
⚠️ The company carries a high price-to-sales ratio of 376.97 and remains unprofitable with negative EPS.
📉 Historical consistency is mixed, with only the latest quarter showing an EPS beat after previous mixed results.
🔮 CleaRank simulations project a base-case price of $85.62 by 2030 but warn of high volatility and a downside path to $23.77.
Bullish Signals
- Insiders have purchased $52.7 million worth of stock against $18.5 million in sales, indicating strong management confidence.
- Analysts forecast next year's revenue to grow by 283% to $61.2 million, driven by the company's pipeline and market potential.
Risk Factors
- The company's price-to-sales ratio of 376.97 is significantly higher than the sector median, posing a valuation risk.
- EPS remains negative, creating a risk if the high growth expectations are not met to justify the premium valuation.
Full Analysis
As of September 19, 2026, CRISPR Therapeutics AG (CRSP) trades at $56.56, with Wall Street analysts maintaining a consensus price target of $80.00, implying approximately 41.4% upside potential. The technical indicators show the stock trading above its 50-day average of $53.03 with an RSI of 46, indicating neutral momentum.
Insider activity reveals a net buying position, with insiders purchasing $52.7 million in stock against $18.5 million in sales, signaling management confidence in the company's future prospects. Analysts forecast significant revenue growth of 283% for the coming year to reach $61.2 million, driven by the company's pipeline and market potential.
Despite the bullish insider sentiment and revenue forecasts, CRSP faces valuation risks with a price-to-sales ratio of 376.97, significantly higher than the sector median, while remaining unprofitable with negative EPS. Historical performance shows that a $10,000 investment in October 2016 would be worth roughly $40,142 today, outperforming the S&P 500 benchmark of $35,546 over the same period.
CleaRank's Monte Carlo simulations project a base-case price near $85.62 by 2030, representing a 1.5x return from current levels, though the model also highlights a downside path ending near $23.77 due to the stock's high volatility and lack of dividends.
